Patent US6063116A successfully refreshed from Google Patents.
US6063116A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Modulation of cell proliferation and wound healing
Assignee: ER Squibb and Sons LLC
•
Filing: 1995-04-24
•
Granted: 2000-05-16
•
Expires: 2015-04-24
Abstract
Abstract PCT No. PCT/US95/13715 Sec. 371 Date Jun. 27, 1997 Sec. 102(e) Date Jun. 27, 1997 PCT Filed Apr. 24, 1995 PCT Pub. No. WO96/13286 PCT Pub. Date May 9, 1996Intraocular devices which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The proliferation modulating agent is associated either covalently or non-covalently with the material from which the intraocular device is prepared, generally a biologically inert polymer which is physiologically compatible with ocular tissue. The intraocular devices are implanted in the tissue, and the drug is released from the intraocular device such that the drug is substantially retained within the implant region. The device may be used to inhibit cellular proliferation around the implant. The device can be provided as a sterile kit, preferably in a form suitable for immediate use.
Inventors
- 👤 Peter J. Kelleher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 16:02
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/54; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/58; A61K47/59; A61K47/595; A61K47/61; A61K47/69; A61K47/6957; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61L27/28; A61P; A61P27/00; A61P43/00; A61L2300/00; A61L2300/40; A61L2300/416
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
72 words
An occular implant comprising: a biologically inert polymer having at least one proliferation inhibiting agent associated therewith by a labile interaction selected from the group consisting of: a hydrophobic interaction and a hydrophilic interaction, such that upon implantation into the eye said proliferation inhibiting agent is gradually released from the implant in a localized region of the eye to thereby inhibit proliferation of target cells in the localized region of the eye.
Claim 2
Dependent Claim
72 words
An occular implant comprising: a biologically inert polymer having at least one proliferation inhibiting agent associated therewith by a labile interaction selected from the group consisting of: a hydrophobic interaction and a hydrophilic interaction, such that upon implantation into the eye said proliferation inhibiting agent is gradually released from the implant in a localized region of the eye to thereby inhibit proliferation of target cells in the localized region of the eye.
Claim 3
Dependent Claim
73 words
An occular implant comprising: a biologically inert polymer having at least one proliferation inhibiting agent associated therewith by a labile covalent bond selected from the group consisting of: a hydrazone bond and a semicarbazone bond, such that upon implantation into the eye said proliferation inhibiting agent is gradually released from the implant in a localized region of the eye to thereby inhibit proliferation of target cells in the localized region of the eye.
Claim 4
Dependent Claim
73 words
An occular implant comprising: a biologically inert polymer having at least one proliferation inhibiting agent associated therewith by a labile covalent bond selected from the group consisting of: a hydrazone bond and a semicarbazone bond, such that upon implantation into the eye said proliferation inhibiting agent is gradually released from the implant in a localized region of the eye to thereby inhibit proliferation of target cells in the localized region of the eye.
Claim 5
Dependent Claim
25 words
The implant according to claim 1, wherein the polymer is selected from the group consisting of polyamides, polypeptides, polyesters, polycarbonates, polyurethanes, polyacetals, polysaccharides, and polyolefins.
Claim 6
Dependent Claim
43 words
The implant according to claim 1, wherein the polymer is selected from the group consisting of silicone rubber, polyurethane rubber, polyethylene, polyvinyl chloride, poly(hydroxyethyl methacrylate), poly(methyl methacrylate), poly(ethyleneterephthalate), polypropylene, polystryene, poly(tetrafluoroethylene), polyglycolic acid, cellulose, ethylcellulose, methycellulose, dextran, carboxymethylcellulose, hyaluronic acid, nylon, and collagen.
Claim 7
Dependent Claim
23 words
The implant according to claim 1, wherein the polymer is a polysaccharide selected from the group consisting of: carboxymethylcellulose, hyaluronic acid, and heparin.
Claim 8
Dependent Claim
22 words
The implant according to claim 1, wherein the proliferation inhibiting agent is selected from the group consisting of: doxirubicin, daunomycin, and 5-fluorouracil.
Claim 9
Dependent Claim
13 words
The implant according to claim 1, wherein said inhibiting agent is a toxin.
Claim 10
Dependent Claim
11 words
The implant according to claim 7, wherein said toxin is ricin.
Claim 11
Dependent Claim
12 words
The implant according to claim 1, wherein said implant is a membrane.
Claim 12
Dependent Claim
28 words
The implant according to claim 1, wherein said implant is selected from the group consisting of an intraocular lens, drainage shunt, a prosthesis, and a lens capsular loop.
Claim 13
Dependent Claim
20 words
The implant according to claim 1, wherein said polymer is selected from the group consisting of silicon, polymetthylmethacrylate, and nylon.
Claim 14
Dependent Claim
18 words
The implant according to claim 1, wherein the polymer is nylon and said proliferation inhibiting agent is daunomycin.
Claim 15
Dependent Claim
37 words
A method for killing residual lens epithelial cells after cataract surgery, said method comprising placing an implant according to claim 1 into an eye during or after said cataract surgery, to thereby kill residual lens epithelial cells.
Claim 16
Dependent Claim
29 words
A method for preventing formation of scar tissue in an eye, said method comprising placing an implant according to claim 1 into a fistula, whereby scar formation is prevented.
Claim 17
Independent Claim
52 words
A method for preparing an intraocular device, said method comprising: contacting a biologically inert polymer with a proliferation inhibiting agent, such that a labile interaction selected from the group consisting of: hydrazone bond, a semicarbazone bond, a hydrophobic interaction, and a hydrophilic interaction between said polymer and said proliferation inhibiting agent results.
Claim 18
Independent Claim
52 words
A method for preparing an intraocular device, said method comprising: contacting a biologically inert polymer with a proliferation inhibiting agent, such that a labile interaction selected from the group consisting of: hydrazone bond, a semicarbazone bond, a hydrophobic interaction, and a hydrophilic interaction between said polymer and said proliferation inhibiting agent results.
References Cited (Backward Citations)
US3416530A
Cited
US4093709A
Cited
US4128318A
Cited
US4170043A
Cited
US4240163A
Cited
US4526938A
Cited
US4671954A
Cited
US4745160A
Cited
US4725428A
Cited
US4766106A
Cited
US4871716A
Cited
EP0267005A2
Cited
US4863457A
Cited
US4918165A
Cited
EP0299467A1
Cited
US4937270A
Cited
US4853224A
Cited
US5098443A
Cited
US5578079A
Cited
US5080924A
Cited
EP0430539A2
Cited
EP0443809A2
Cited
WO1995003783A1
Cited
US5017229A
Cited
US5246698A
Cited
EP0488401A1
Cited
US5501856A
Cited
WO1995033492A1
Cited
US5554187A
Cited
US5728751A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-05-16 | 2003-11-15 | 2004-05-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-05-16 | 2007-11-15 | 2008-05-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-05-16 | 2011-11-15 | 2012-05-16 | $7700.00 | Window Closed / Lapsed |